COMPASS Pathways plc CMPS
COMPASS Pathways plc (Nasdaq: CMPS) is a CNS/neurology/psychiatry drug developer. Its lead program, COMP360 psilocybin treatment, is in Phase 3 for Treatment-resistant depression (TRD). Its next catalyst on record is COMP360 in TRD: Potential FDA approval and first product revenue (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: COMP360 in TRD — Potential FDA approval and first product revenue (2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| COMP360 (COMP005 and COMP006 pivotal trials) | Treatment-resistant depression | small molecule | Phase 3 |
| COMP360 (COMP202) | PTSD | small molecule | Phase 2 |
Recent results and decisions
- Aug 5, 2026started Late-stage (Phase 2b/3) PTSD trial is underway.
Compass continues to progress PTSD program, with late-stage trial underway.
Filing - Jul 7, 2026positive 26-week data from COMP006 and COMP005 show rapid onset and durability through at least 6 months; primary endpoint at Week 6 previously met (P<0.001) in both trials.
COMP006 and COMP005 26-week data demonstrate rapid onset and remarkable durability through at least 6 months further validating COMP360’s differentiated profile in highly chronic TRD
Filing - May 13, 2026accepted FDA granted rolling NDA submission and review; sections of the NDA already submitted, final submission on track for Q4 2026.
FDA granted Compass NDA rolling submission and review request, based on strength of positive Phase 3 data.
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.